

Gastrointestinal tract symptoms in coronavirus disease 2019: Analysis of clinical symptoms in adult patients

Yong Zhang^{1*}, Zuneng Lu¹, Bo Wang², Jinxing Cang³, Yonggang Ma⁴

1. Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China

2. Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China

3. Department of Cardiac Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China

4. Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China

Corresponding author: Yong Zhang

ABSTRACT

Objective: To investigate the clinical presentation of coronavirus disease 2019 (COVID-19), particularly the incidence of gastrointestinal tract symptoms.

Design: We enrolled adult COVID-19 patients from a mobile cabin hospital in Wuhan with a definitive diagnosis by SARS-CoV-2 nucleic acid testing. Face-to-face interviews were conducted in which the patient selected COVID-19-related symptoms and report the time of onset and duration of symptoms.

Results: A total of 212 adults were enrolled in this study, of which 127 (59.9%) were females, mean age was 48.50 ± 13.15 (range: 17-79) years, and mean disease course was 26.78 ± 9.16 (3-60) days. Fever and cough were the most common and earliest clinical symptoms of COVID-19.

Diarrhoea occurred in 43.8% (93/212) of patients, of which 86.0% (80/93) had mushy stools. Nausea and vomiting were also common (20.7%). Diarrhoea lasted for 4.00(2.00-8.85) days and mostly occurred 5.00(0.25-11.00) days after the emergence of the first symptoms. Multiple logistic regression analysis found that diarrhoea was significantly correlated with fatigue [OR2.900,95%CI (1.629-5.164), $p<0.0001$].

Conclusions: Gastrointestinal tract symptoms are common in COVID-19 and most occur during the middle stage of the disease and lasts for a short period of time. Clinicians need to pay greater attention to gastrointestinal tract symptoms of COVID-19.

Key words: Diarrhoea, Infection disease, Gastrointestinal tract

INTRODUCTION

Coronavirus disease 2019 (COVID-19) has recently become a global pandemic.¹ Fever and cough are the most common clinical presentations.²⁻³ Gastrointestinal tract symptoms such as nausea, vomiting, and diarrhoea are often seen in coronavirus infections such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).⁴⁻⁵ Recent studies report that gastrointestinal tract symptoms are rarely observed in COVID-19 patients,²⁻³ observed in about 3.0% of cases. However, a US report revealed that the first patient experienced 2 continuous days of diarrhoea on Day 6 after disease onset.⁶ Are gastrointestinal tract symptoms rare in COVID-19? We recently worked in a mobile cabin hospital and conducted a detailed investigation of the clinical symptoms of patients with COVID-19.

METHODS

Ethical considerations

This study was reviewed by the ethics committee of Renmin Hospital of Wuhan University (Ethics Approval No.: WDRY2020-K033) and written informed consent from patients was waived. Only verbal explanation was required, and verbal informed consent was obtained from the patients.

Subject population

Hardcopy forms were formulated and printed. From February 18 to March 2, 2020, COVID-19 patients ≥ 16 years of age in Wuchang mobile cabin hospital were recruited. The patients themselves completed a form that collected general demographic information, current medical history, past medical history, date of first positive SARS-CoV-2 nucleic acid result, chest CT result, and COVID-19 contact history. COVID-19-related clinical symptoms were listed with tick boxes in the form. The study participants were asked to check the boxes of their recent symptoms

and write down the specific date of onset and duration of each symptom. All patients in this mobile cabin hospital were long-time residents of Wuhan and tested positive for SARS-CoV-2 nucleic acid by reverse transcription polymerase chain reaction (RT-PCR), and their diseases were classified as mild and moderate COVID-19 according to the diagnostic criteria in Diagnosis and Treatment Plan of Coronavirus Disease 2019 (trial edition 5).⁷ After patients completed the hardcopy forms, photographs were taken, and the data were uploaded onto the network. Before the mobile cabin hospital was closed, the hardcopy forms were destroyed as medical waste.

Data analysis

SPSS 26.0 software was used for statistical analysis. Disease course referred to the duration from onset of first symptoms to the date of the investigation. Disease course in asymptomatic patients was defined as the interval from test date of the positive SARS-CoV-2 nucleic acid test result to the date of the investigation. Symptom duration was defined as the interval from onset of that symptom to resolution or investigation. Symptom occurrence node refers to the duration from onset of the first symptom of COVID-19. High fever was defined as temperature $\geq 39^{\circ}\text{C}$. Patients with ages ≥ 50 years were described as elderly patients. A disease course ≥ 20 days was defined as long disease course. A history of chronic disease was defined as other diseases that persisted for 3 months before COVID-19 such as hypertension, diabetes, hepatitis B, and tuberculosis. The Kolmogorov-Smirnov test was used to determine whether the data were normally distributed. Continuous variables were expressed as the means and standard deviations or medians and interquartile ranges (IQR) as appropriate. Categorical variables were summarized as the counts and percentages in each category. We grouped patients into diarrhoea and non-diarrhoea. Wilcoxon rank-sum tests were applied to continuous variables, chi-square tests and Fisher's exact tests were used for categorical variables as appropriate. To identify risk factors for COVID-19, Pearson's chi-squared test was used for correlation analysis. Differences with a P-value < 0.05 were considered statistically significant.

RESULTS

A total of 212 adults were enrolled in the study, of which 127 (59.9%) were females, and mean age was 48.50 ± 13.15 (range: 17–79) years. In terms of educational level, 8.0% (17/212) completed elementary school education, 52.8% (112/212) attained middle school education, and 39.2% (83/212) were college graduates. Mean disease course was 26.78 ± 9.16 (range: 3–60) days. There were 12 clinically asymptomatic patients, and mean disease course was 18.08 ± 9.32 (range: 9–33) days. Five of these 12 patients had chest computed tomography (CT) scans that showed viral pneumonia but they had no clinical presentation. Approximately 44.3% of the patients claimed to have a clear contact history with individuals with COVID-19. Chest CT scans showed that almost all patients (96.7%, 207/212) in this study had specific characteristics for COVID-19.⁷

Fever and cough were the most common clinical presentations (Figure 1), and patients with high-grade fever accounted for 14.2% (30/212). Profuse sweating occurred in 114 patients, of which 89.5% (102/114) had night sweats. Diarrhoea occurred in 43.8% (93/212) of patients, of which 86.0% (80/93) had mushy stools. Nausea and vomiting were also common (20.7%). Around 3.3% (7/212) of the patients developed conjunctival congestion.

Cough was the most persistent symptom, whereas conjunctival congestion had the shortest duration. Diarrhoea persisted for a median duration of 4.00 (2.00–8.75) days and is one of the clinical symptoms with the shortest duration.

Nasal congestion, myalgia, headache, chills, fever, fatigue, and coughing were common initial symptoms, whereas gastrointestinal tract symptoms were rare initial symptoms. In this study, 5 (2.4%) patients had an initial symptom of diarrhoea, whereas most patients developed diarrhoea 5.00(0.25–11.00) days (median) after the development of initial symptoms (Figure 3).

Correlation analysis of diarrhoea found that fatigue had the highest correlation with diarrhoea \square OR, 2.900, 95% CI(1.629-5.164), $p < 0.0001$ \square . Diarrhoea was not associated with sex or disease course ($P > 0.05$), and old age might be a protective factor against diarrhoea (OR, 0.552, 95% CI (0.319-0.955))(Table 1).

DISCUSSIONS

Coronavirus is a large virus family that can cause various conditions ranging from the common cold to severe infectious diseases such as SARS and MERS.⁸ COVID-19 is a recently discovered infection in humans and is now considered a pandemic.^{1,9} The most common clinical presentations associated with coronavirus infection are fever and cough.^{2-3,9} The results of this study have further proven previous conclusions. Studies have found that gastrointestinal tract symptoms are one of the common clinical presentations in SARS and MERS.^{4-5,9} However, recent studies found that diarrhoea is rare in COVID-19,^{2-3,10} with an incidence of about 3%. A US study reported that their first patient, who had mild COVID-19, developed diarrhoea lasting for 2 days.⁶ In addition, a study reported that diarrhoea may be an initial symptom of COVID-19.¹¹ In this study, we found that a minority of patients had an initial symptom of diarrhoea. In contrast to the results of previous studies, this study found that diarrhoea, nausea, and vomiting are common in COVID-19. Why are there differences between the results of this study and other past clinical investigations? First, the data sources of these studies vary. The information used by Zhong et al. was obtained from medical records,^{3,10} whereas the data in this study was provided by the patients themselves. Even though this is a retrospective study, the study subjects were adults and most had an educational level of middle school and above, thereby ensuring the reliability and authenticity of the content of this study. Second, the time nodes of the data records are different. The results of this study found that diarrhoea mostly occurred 5 days after the development of initial symptoms; therefore, patients may not have developed gastrointestinal tract symptoms such as diarrhoea, nausea, and vomiting in the other studies. In this study, the mean disease course when patients underwent

interviews was 26.78 ± 9.16 days, which far exceeds the duration in other studies. For example, Gong et al. showed that the mean disease course of deceased patients was 10.56 ± 4.42 days.¹² Furthermore, in contrast to cough and other symptoms, diarrhoea in COVID-19 patients lasted for a short duration and mostly occurred as mushy stools instead of watery diarrhoea in SARS.⁴ Therefore, diarrhoea may be overlooked by clinicians and patients during COVID-19. As digestive tract symptoms such as diarrhoea, nausea, and vomiting tend to be overlooked in coronavirus infections, Kim et al. proposed considering diarrhoea as one of the clinical presentations during MERS diagnosis.¹³

Why do we need to pay attention to gastrointestinal tract symptoms such as diarrhoea, nausea, and vomiting? First, as COVID-19 is a wasting disease, vomiting and diarrhoea affect nutrient absorption in patients and therefore may affect disease outcomes. Our study found that diarrhoea is significantly correlated with fatigue, suggesting that diarrhoea may decrease the quality of life of patients. Hence, clinicians must actively strengthen nutrition supportive treatment in COVID-19 patients. In addition, Xiao et al. isolated viable SARS-CoV-2 virus from fecal samples of COVID-19 patients and the human receptor for SARS-CoV-2, angiotensin-converting enzyme,¹⁴ is highly expressed in the stomach, duodenum, and rectal epithelial cells, supporting the possibility that SARS-CoV-2 can enter host cells in the digestive tract. Gu et al. proposed that the digestive tract may be one of the target organs of SARS-CoV-2.¹⁵ Our study showed that digestive tract symptoms such as diarrhoea, nausea, and vomiting are common in COVID-19, suggesting that the possibility of fecal–oral transmission is high. Therefore, we need to actively promote hand hygiene to prevent this disease. Moreover, public health authorities need to actively manage digestive tract excretions from patients to prevent the spread of COVID-19.

As the subjects of this study are patients with mild cases in mobile cabin hospitals, we were unable to determine whether gastrointestinal tract symptoms are common in severe patients. Therefore, we can only suggest that digestive tract symptoms such as diarrhoea, nausea, and

vomiting are common in mild COVID-19. At present, no large-scale study has discovered the SARS-CoV-2 virus in fecal samples.¹⁴ Therefore, a large sample size of COVID-19 patients is required for a study in which stool samples should be collected approximately one week after the onset of initial clinical symptoms in COVID-19 patients to assess the proportion of COVID-19 patients with stool samples containing the SARS-CoV-2 virus. This will provide valuable evidence to support aggressive public health strategies.

In conclusion, gastrointestinal tract symptoms are common in COVID-19 and most occur during the middle stage of the disease and lasts for a short period of time. Clinicians need to pay greater attention to the gastrointestinal tract symptoms of COVID-19.

ACKNOWLEDGEMENTS

The authors would like to thank all patients for making this study possible. Mourn to the victims.

CONTRIBUTORS

YZ conceived and designed the study. BW, JXC and YGM performed the experiments and performed the literature survey. YZ and ZNL contributed to the writing and checking of the letter.

Funding No funding.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which

permits others to distribute, remix, adapt, build upon this work non-commercially,

and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Yong Zhang <http://orcid.org/0000-0002-1525-2329>

REFERENCES

- 1 World Health Organization. Novel Coronavirus (2019-nCoV) situation reports.

https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200310-sitrep-50-covid-19.pdf?sfvrsn=55e904fb_2 (Assessed on March 10th, 2020)
- 2 Jiang F, Deng L, Zhang L, et al. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med 2020 Mar 4. doi: 10.1007/s11606-020-05762 w. [Epub ahead of print]
- 3 Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020 Feb 28. doi: 10.1056/NEJMoa2002032. [Epub ahead of print]
- 4 Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 2003;125:1011-7.
- 5 Choi WS, Kang CI, Kim Y, et al. Clinical presentation and outcomes of Middle East Respiratory Syndrome in the Republic of Korea. Infect Chemother 2016; 48:118–26.

- 6 Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med* 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
- 7 National Health Commission of the People's Republic of China. Update on novel coronavirus-infected pneumonia situation as of 24:00 on February 8, 2020. <http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fc1e3e13a.shtml>
- 8 World Health Organization. <https://www.who.int/health-topics/coronavirus>
- 9 Meo SA, Alhowikan AM, Al-Khlaiwi T, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *Eur Rev Med Pharmacol Sci* 2020; 24:2012-19.
- 10 Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395:497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
- 11 Song Y, Liu P, et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. *Gut* 2020 Mar 5. pii: gutjnl-2020-320891.
- 12 Li X, Wang LX, Yan SN, et al. Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China. medRxiv preprint doi: <https://doi.org/10.1101/2020.02.19.20025239>.
- 13 Kim MN, Kim EC. Considering Revision the Criteria for Patients under Investigations for MERS-CoV Infections: Diarrhea or Not. *J Korean Med Sci* 2018; 33:e344. doi: 10.3346/jkms.2018.33.e344. eCollection 2018 Dec 31.

- 14 Xiao F, Tang MW, Zheng XB et al. Evidence for gastrointestinal tract infection of SARS-CoV-2. *Gastroenterol* 2020; DOI: 10.1053/j.gastro.2020.02.055.
<https://www.medrxiv.org/content/10.1101/2020.02.17.20023721v1>
- 15 Gu JY, Han B, Wang J. COVID-19: Gastrointestinal tract manifestations and potential fecal-oral transmission. *Gastroenterol* 2020; DOI: 10.1053/j.gastro.2020.02.054.




Figure 1 Incidence of clinical symptoms




Figure 2 Duration of clinical symptoms

Notes: the data above is medium.




Figure 3 Occurrence node of clinical symptoms

Notes: the data above is medium.

Table1 The related factors with diarrhoea

Factors	Diarrhoea, n (%)		P value	HR(95%CI)
	Yes (93)	No (119)		
Female	55 □ 59.1 □	38 □ 40.9 □	0.841	1.058(0.609-1.840)
Old age	41 □ 44.1 □	70 □ 58.3 □	0.034	0.552(0.319-0.955)
Long duration	80 □ 86.0 □	91 □ 76.5 □	0.081	1.893(0.919-3.902)
Chronic disease	41 □ 40.3 □	53 □ 47.8 □	0.395	0.739(0.368-1.485)
Fever	80 □ 86.0 □	87 □ 73.1 □	0.025	2.263(1.110-4.616)
Chill	28 □ 30.1 □	35 □ 29.4 □	0.913	1.034(0.571-1.871)
Cough	70 □ 75.3 □	70 □ 58.8 □	0.013	2.130(1.174-3.866)
Sputum	61 □ 65.6 □	50 □ 42.0 □	0.001	2.631(1.500-4.613)
Shortness of breath	47 □ 50.5 □	42 □ 35.3 □	0.026	1.873(1.077-3.259)
Headache	36 □ 38.7 □	24 □ 20.2 □	0.003	2.500(1.356-4.610)
Sore throat	37 □ 39.8 □	35 □ 29.4 □	0.115	1.586(0.894-2.811)
Conjunctival congestion	6 □ 6.5 □	1 □ 0.8 □	0.054	8.138(0.962-68.882)

Nasal congestion	9□9.7□	8□6.7□	0.434	1.487(0.550-4.015)
Myalgia	35□37.6□	23□19.3□	0.003	2.519(1.356-4.677)
Fatigue	47□50.5□	31□26.1□	<0.001	2.900(1.629-5.164)
Excessive sweating	61□65.6□	54□45.4□	0.004	2.295(1.311-4.016)
Nausea or vomiting	27□29.0□	17□14.3□	0.010	2.455(1.242-4.851)

Notes: HR, hazard ratio; CI, confidence interval